多汗症治療市場規模、佔有率、成長分析、按類型、按治療方法、按年齡、按最終用戶、按地區 - 行業預測，2025-2032

2023年，全球多汗症治療市場規模為6.712億美元，在預測期內（2025-2032年）複合年成長率為5.4%，從2024年的7.0744億美元成長到2032年，預計將成長至10.775億美元。

由於研發投資的活性化和次發性多汗症盛行率的上升，多汗症治療市場正在顯著成長。由於沒有永久治療方法，止汗劑和外用溶液仍然是主要治療方法。患者對創新治療方案的偏好不斷增加，促使公司增強其產品。根據 Jared Brackenrich 於 2021 年 10 月發表的一項研究，多汗症目前影響著約 3% 的美國人口，而這種狀況影響社會、心理和職業功能。此外，有希望的治療方法開發、有利的報銷政策和公眾意識的提高可能會推動需求。特別是，Brickell Biotech 的索吡溴銨凝膠的 3 期臨床試驗顯示了先進多汗症治療的強大未來性。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術分析
• 監管分析
• 專利分析
• 案例研究

多汗症治療市場規模：按類型和複合年成長率（2025-2032）

• 市場概況
• 腋窩多汗症
• 手掌多汗症
• 足底多汗症
• 其他類型

多汗症治療市場規模：依治療方法及複合年成長率（2025-2032）

• 市場概況
• 局部治療
• 口腔醫學
  • 抗膽鹼能藥物
  • 其他口服藥物
• 肉毒毒素注射
• 離子電滲透療法
• 手術治療

多汗症治療市場規模：依年齡及複合年成長率（2025-2032）

• 市場概況
• 直到 50 歲
• 50歲以上

多汗症治療市場規模：按最終用戶和複合年成長率（2025-2032）

• 市場概況
• 醫院
• 門診手術中心
• 皮膚科診所
• 其他最終用戶

多汗症治療市場規模：按地區和複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• AbbVie Inc.（US）
• Avanor Healthcare Ltd.（UK）
• Brickell Biotech Inc.（US）
• Dermadry Laboratories Inc.（Canada）
• Dermavant Sciences Inc.（US）
• Hugel, Inc.（South Korea）
• Eirion Therapeutics, Inc.（US）
• Eli Lilly and Company（US）
• Intas Pharmaceuticals Ltd.（India）
• Kaken Pharmaceutical Co., Ltd.（Japan）
• Maruho Co., Ltd.（Japan）
• miraDry, Inc.（US）
• SweatBlock（US）
• Roivant Sciences Ltd.（Switzerland）
• Theravida, Inc.（US）
• Dr. August Wolff GmbH（Germany）
• Dr. Reddy's Laboratories Ltd.（India）
• GSK Plc（UK）
• Revance（US）
• NovaMedica（Russia）

結論和建議

Global Hyperhidrosis Treatment Market size was valued at USD 671.2 million in 2023 and is poised to grow from USD 707.44 million in 2024 to USD 1077.5 million by 2032, growing at a CAGR of 5.4% during the forecast period (2025-2032).

The hyperhidrosis treatment market is witnessing significant growth driven by heightened R&D investment and a rising prevalence of secondary hyperhidrosis disorders. Antiperspirants and topical solutions remain the frontline therapies as no permanent cure exists. The growing patient preference for innovative treatment options has spurred companies to enhance their offerings. Currently, hyperhidrosis affects about 3% of the U.S. population, according to a study published by Jared Brackenrich in October 2021, underscoring the condition's impact on social, psychological, and vocational functioning. Additionally, promising therapies in the pipeline, favorable reimbursement policies, and increasing public awareness are likely to fuel demand. Notably, Brickell Biotech's Phase 3 trials of sofpironium bromide gel indicate a strong future potential for advanced hyperhidrosis treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hyperhidrosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hyperhidrosis Treatment Market Segmental Analysis

Global Hyperhidrosis Treatment Market is segmented by Type, Treatment, Age, End-user and region. Based on Type, the market is segmented into Axillary hyperhidrosis, Palmar hyperhidrosis, Plantar hyperhidrosis and Other types. Based on Treatment, the market is segmented into Topical treatment, Oral medication, Botulinum toxin injections, Iontophoresis and Surgical treatment. Based on Age, the market is segmented into Up to 50 years and Above 50 years. Based on End-user, the market is segmented into Hospitals, Ambulatory surgical centers, Dermatology clinics and Other end-users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hyperhidrosis Treatment Market

The Global Hyperhidrosis Treatment market is driven by a growing interest among healthcare providers in exploring advanced therapies such as radiofrequency microneedling for hyperhidrosis patients. Researchers are particularly focused on assessing the long-term effectiveness of fractional microneedle radiofrequency treatments for individuals with primary axillary hyperhidrosis, utilizing the hyperhidrosis disease severity scale (HDSS) to measure significant improvements post-treatment. Additionally, tap water iontophoresis is gaining traction, demonstrating notable results in clinical trials for patients suffering from plantar and palmar hyperhidrosis. Innovations in treatment options are being propelled by recent successful studies, including the positive Phase 3 results from Brickell Biotech Inc. regarding sofpironium bromide gel, highlighting the market's potential for growth and enhanced patient quality of life.

Restraints in the Global Hyperhidrosis Treatment Market

The Global Hyperhidrosis Treatment market faces notable challenges, one of which is the limited duration of effectiveness associated with Botulinum toxin injections; patients often develop a reduced response to these treatments over time. Additionally, the financial implications and emotional strain on patients pose significant obstacles, as many insurance providers do not reimburse expenses related to hyperhidrosis treatments. This lack of coverage not only adds to the economic burden for individuals seeking relief but also contributes to their psychological distress, potentially leading to decreased treatment adherence and limiting market growth opportunities in this sector.

Market Trends of the Global Hyperhidrosis Treatment Market

The Global Hyperhidrosis Treatment market is witnessing significant growth, driven by an increasing awareness of excessive sweating conditions and the effectiveness of advanced treatment options like onabotulinumtoxinA (Botox). With its clinically proven ability to reduce sweating by 82-87% and long-lasting effects that can endure up to 14 months, Botox has become a preferred treatment choice among patients. The market is further propelled by innovations in minimally invasive procedures, a growing prevalence of hyperhidrosis, and a rise in disposable income allowing for aesthetic treatments. As demand expands, the market is poised for continued advancement through research and new therapeutic options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Hyperhidrosis Treatment Market Size by Type & CAGR (2025-2032)

• Market Overview
• Axillary hyperhidrosis
• Palmar hyperhidrosis
• Plantar hyperhidrosis
• Other types

Global Hyperhidrosis Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Topical treatment
• Oral medication
  • Anticholinergics
  • Other oral medications
• Botulinum toxin injections
• Iontophoresis
• Surgical treatment

Global Hyperhidrosis Treatment Market Size by Age & CAGR (2025-2032)

• Market Overview
• Up to 50 years
• Above 50 years

Global Hyperhidrosis Treatment Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Dermatology clinics
• Other end-users

Global Hyperhidrosis Treatment Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Age, End-user)
  • US
  • Canada
• Europe (Type, Treatment, Age, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Age, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Age, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Age, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avanor Healthcare Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Brickell Biotech Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermadry Laboratories Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermavant Sciences Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hugel, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eirion Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaken Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Maruho Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• miraDry, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SweatBlock (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roivant Sciences Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravida, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. August Wolff GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revance (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NovaMedica (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations